Comparative Pharmacology
Head-to-head clinical analysis: EQUETRO versus PARADIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EQUETRO versus PARADIONE.
EQUETRO vs PARADIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Equetro (carbamazepine extended-release) is an anticonvulsant and mood stabilizer. It stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing synaptic transmission. It also potentiates GABA receptors and inhibits glutamate release.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Initial: 50 mg orally twice daily; increase by 50-100 mg/day every 2-4 weeks. Usual maintenance: 100-200 mg orally twice daily. Maximum: 200 mg orally twice daily.
100 mg orally three times daily; maximum 600 mg/day.
None Documented
None Documented
Carbamazepine: 25-65 hours (initial single dose), 12-17 hours (chronic dosing due to autoinduction); carbamazepine-10,11-epoxide: 5-8 hours.
12-24 hours (terminal); prolonged in renal impairment
Renal: 2% excreted unchanged (carbamazepine) in urine; 15% as carbamazepine-10,11-epoxide; 30% as other metabolites; biliary/fecal: 50-60% as metabolites.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Category C
Category C
Anticonvulsant
Anticonvulsant